Advances in treatment of triple negative breast cancer
10.3781/j.issn.1000-7431.2017.55.700
- Author:
Jibo ZHANG
1
Author Information
1. Department of Breast Medical Oncology, Cancer Hospital of Tianjin Medical University, Tianjin Clinical Research Center for Cancer
- Publication Type:Journal Article
- Keywords:
Adjuvant chemotherapy;
Breast neoplasms;
Immunotherapy;
Neoadjuvant chemotherapy;
Targeted therapy;
Triple negative breast cancer
- From:
Tumor
2017;37(7):788-794
- CountryChina
- Language:Chinese
-
Abstract:
Breast cancer is the most common malignant tumor in females in the world. The characteristics of triple-negative breast cancer (TNBC) are defined as estrogen receptor (ER)-negative, progesterone receptor (PR)-negative and human epidermal growth factor receptor 2 (HER2)-negative. TNBC accounts for about 15%-20% in all the pathological types of breast cancer. With poor prognosis, high recurrence rate and high mortality rate, TNBC has become the focus of the research recently. At present, the treatment methods of breast cancer include surgery, neoadjuvant chemotherapy, adjuvant chemotherapy, endocrine therapy and targeted therapy, etc. Due to the lack of ER, PR and HER2 expressions, patients can not benefit from the endocrine therapy and anti-HER2 targeted therapy. Chemotherapy is currently recommended for the treatment of TNBC. Many chemotherapeutic regimens and new drugs are being explored. This paper reviews the progress in chemotherapy, endocrine therapy, targeted therapy and immunotherapy of TNBC.
